Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2010

View Archived Issues

Memantine reduces "off" time in Parkinson's disease

PYM-50028 can be delivered to patients with PD at preclinically efficacious doses

Proximagen Neuroscience claims new SSAO inhibitors

New JAK3 kinase inhibitors identified by Roche

Novartis claims new chemokine CXCR2 receptor antagonists

Astellas submits MAA for mirabegron in Japan

Taxus Element paclitaxel-eluting stent system launched in Europe

Roche amends trial protocols for taspoglutide phase III program

Phase I/II trial of new proapoptotic agent APR-246 advances

PX-478 shows antitumor activity in phase I trial in advanced solid tumors

177Lu-J591 shows safety and preliminary efficacy in metastatic CRPC

ALD-518 improves rheumatoid arthritis symptoms in phase II trial

FDA recommends approval of emergency contraceptive ulipristal

Bionomics completes phase I trial of BNC-210 for anxiety

Mitsubishi Tanabe's Remicade approved for ulcerative colitis in Japan

FDA committee recommends additional clinical testing to support flibanserin NDA

Valeant and Biovail agree to merge

Hematide shows promise to treat anemia in phase III trials in CRF

BL-1020 improves schizophrenia symptoms in phase IIb trial

Amplyx Pharmaceuticals presents novel carbapenems

Zydus receives permission for phase I trial of ZYOG-1 in India

Lodotra now available in 13 European countries for RA

Sosei to acquire Activus Pharma

FDA advises on phase III palifosfamide trial in metastatic soft tissue sarcoma

Exelixis regains rights to XL-184

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...